Chronisch thromboembolische pulmonale Hypertonie: Empfehlungen der Kölner Konsensus Konferenz 2016

6533b830fe1ef96bd12966cd

RESEARCH PRODUCT

Chronisch thromboembolische pulmonale Hypertonie: Empfehlungen der Kölner Konsensus Konferenz 2016

B. C. Meyer Matthias Held H.-j. Schäfers Silvia Ulrich Thorsten Kramm Alexander C. Bunck A. Grgic Stavros Konstantinides U. Krüger Hans-jürgen Seyfarth Mareike Lankeit Michael Schmidt Eckhard Mayer Felix Gerhardt I. Lang M. Gerges S. Guth J Hinrichs Walter Klepetko Christian Grohé Christoph B. Wiedenroth K Olsson Marius M. Hoeper Heinrike Wilkens

subject

medicine.medical_specialty business.industry medicine.medical_treatment Consensus conference 610 Medicine & health 2700 General Medicine General Medicine 030204 cardiovascular system & hematology medicine.disease Pulmonary hypertension 3. Good health Pulmonary endarterectomy 03 medical and health sciences 0302 clinical medicine Pharmacotherapy 030228 respiratory system Angioplasty medicine.artery Pulmonary artery medicine Chronic thromboembolic pulmonary hypertension 10178 Clinic for Pneumology Intensive care medicine business Pediatric cardiology

description

The 2015 European Guidelines on Pulmonary Hypertension did not cover only pulmonary arterial hypertension (PAH), but also other significant subgroups of pulmonary hypertension (PH). In June 2016, a Consensus Conference organized by the PH working groups of the German Society of Cardiology (DGK), the German Society of Respiratory Medicine (DGP) and the German Society of Pediatric Cardiology (DGPK) was held in Cologne, Germany to discuss open and controversial issues surrounding the practical implementation of the European Guidelines. Several working groups were initiated, one of which was dedicated to the diagnosis and treatment of chronic thromboembolic pulmonary hypertension (CTEPH). In every patient with PH of unknown cause CTEPH should be excluded. The primary treatment option is surgical pulmonary endarterectomy (PEA) in a specialized multidisciplinary CTEPH center. Inoperable patients or patients with persistent or recurrent CTEPH after PEA are candidates for targeted drug therapy. For balloon pulmonary angioplasty (BPA), there is currently only limited experience. This option - as PEA - is reserved to specialized centers with expertise for this treatment method. In addition, a brief overview is given on pulmonary artery sarcoma, since its surgical treatment is often analogous to PEA. The recommendations of this working group are summarized in the present paper.

year	journal	country	edition	language
2016-10-19	DMW - Deutsche Medizinische Wochenschrift

https://doi.org/10.1055/s-0042-114529